Ranking · Summer 2019 · Healthcare · Therapeutics

GEn1E Lifesciences

AI platform accelerating therapies for rare & inflammatory diseases.

6.2%

odds of being acquired in the next two years

0.9× the average (6.8%)

#2491 of 4,339 active YC companies · top 58%

Team size not listed · San Francisco, CA, USA

Raises the odds

↑ “platform” in its one-liner

↑ based in United States of America

↑ based in America / Canada

↑ changed its name (pivot)

Lowers the odds

↓ industry: Healthcare

↓ tag: Artificial Intelligence

↓ team size not listed

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads GEn1E Lifesciences's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

gen1e.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub